News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
330,328 Results
Type
Article (19787)
Company Profile (128)
Press Release (310413)
Section
Business (105284)
Career Advice (879)
Deals (18520)
Drug Delivery (93)
Drug Development (50705)
Employer Resources (79)
FDA (7666)
Job Trends (7729)
News (185696)
Policy (17318)
Tag
Academia (726)
Alliances (27793)
Alzheimer's disease (598)
Antibody-drug conjugate (ADC) (71)
Approvals (7650)
Artificial intelligence (106)
Bankruptcy (171)
Best Places to Work (5542)
Biosimilars (74)
Breast cancer (93)
Cancer (815)
Cardiovascular disease (78)
Career advice (711)
Cell therapy (121)
Clinical research (42222)
Collaboration (351)
Compensation (113)
COVID-19 (1086)
C-suite (95)
Data (828)
Diabetes (115)
Diagnostics (1764)
Drug pricing (101)
Earnings (38425)
Employer resources (73)
Events (48037)
Executive appointments (336)
FDA (8066)
Funding (235)
Gene therapy (108)
GLP-1 (533)
Government (1814)
Healthcare (5882)
Infectious disease (1146)
Inflammatory bowel disease (74)
Interviews (115)
IPO (7349)
Job creations (2433)
Job search strategy (648)
Layoffs (262)
Legal (4094)
Lung cancer (128)
Manufacturing (158)
Medical device (1959)
Medtech (1962)
Mergers & acquisitions (11326)
Metabolic disorders (399)
Neuroscience (835)
NextGen: Class of 2025 (2357)
Non-profit (905)
Northern California (856)
Obesity (254)
Opinion (181)
Patents (93)
People (33182)
Pharmaceutical (74)
Phase I (13205)
Phase II (17866)
Phase III (14357)
Pipeline (406)
Policy (83)
Postmarket research (1618)
Preclinical (4597)
Radiopharmaceuticals (159)
Rare diseases (191)
Real estate (3167)
Regulatory (12312)
Research institute (816)
Resumes & cover letters (139)
Southern California (790)
Startups (2007)
United States (7921)
Vaccines (232)
Weight loss (211)
Date
Today (70)
Last 7 days (336)
Last 30 days (1462)
Last 365 days (17502)
2025 (1507)
2024 (17691)
2023 (19644)
2022 (25868)
2021 (26645)
2020 (24875)
2019 (20067)
2018 (15587)
2017 (17260)
2016 (16203)
2015 (18803)
2014 (14788)
2013 (12558)
2012 (13485)
2011 (13819)
2010 (12739)
Location
Africa (409)
Asia (24673)
Australia (3183)
California (1971)
Canada (916)
China (231)
Colorado (81)
Connecticut (77)
Europe (50942)
Florida (323)
Illinois (200)
Indiana (144)
Japan (85)
Maryland (293)
Massachusetts (1657)
Minnesota (111)
New Jersey (774)
New York (576)
North Carolina (416)
Northern California (856)
Ohio (70)
Pennsylvania (460)
South America (608)
Southern California (790)
Texas (257)
Washington State (173)
330,328 Results for "pmv pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.
May 29, 2024
·
5 min read
Pharm Country
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
PMV Pharmaceuticals, Inc today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June.
May 30, 2024
·
1 min read
Press Releases
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 8, 2024
·
11 min read
Press Releases
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial
October 24, 2024
·
9 min read
Business
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
8 min read
Pharm Country
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) today announced that David Mack, Ph.D., President and Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference taking place in Boston, Massachusetts March 4-6, 2024.
February 26, 2024
·
1 min read
Business
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
February 29, 2024
·
9 min read
Pharm Country
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced a strategic reduction of its workforce by approximately 30%.
January 18, 2024
·
5 min read
Business
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, announced key appointments across its leadership team.
January 5, 2024
·
5 min read
Business
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
PMV Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
November 9, 2023
·
8 min read
1 of 33,033
Next
